FLT4 and prostate carcinoma: Recent studies show that VEGFR-3 is expressed on tumour cells in a variety of human malignancies, including non-small cell lung cancer tumours [24,25], breast cancer [26], colorectal adenocarcinoma [27,28], head and neck carcinomas [29,30], and prostate carcinoma [31].